Teleflex (NYSE:TFX) Hits New 12-Month Low – What’s Next?

Teleflex Incorporated (NYSE:TFX)’s share price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $103.97 and last traded at $104.60, with a volume of 515526 shares changing hands. The stock had previously closed at $124.75.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Zacks Research lowered Teleflex from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 30th. Wells Fargo & Company reduced their target price on shares of Teleflex from $137.00 to $131.00 and set an “equal weight” rating on the stock in a research note on Friday, August 1st. Mizuho raised their target price on shares of Teleflex from $130.00 to $135.00 and gave the company a “neutral” rating in a research note on Friday, August 1st. Royal Bank Of Canada raised their target price on shares of Teleflex from $130.00 to $135.00 and gave the company a “sector perform” rating in a research note on Friday, August 1st. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Teleflex in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Teleflex has an average rating of “Reduce” and an average target price of $141.57.

Teleflex Trading Down 12.1%

The company has a current ratio of 2.41, a quick ratio of 1.44 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $4.85 billion, a P/E ratio of 25.77, a PEG ratio of 1.79 and a beta of 1.05. The business has a 50 day moving average price of $126.36 and a 200 day moving average price of $123.37.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, November 6th. The medical technology company reported $3.67 EPS for the quarter, beating analysts’ consensus estimates of $3.38 by $0.29. The company had revenue of $892.90 million during the quarter, compared to analysts’ expectations of $892.79 million. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.Teleflex’s revenue was up 19.4% on a year-over-year basis. During the same period in the prior year, the business posted $3.49 EPS. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS. Analysts anticipate that Teleflex Incorporated will post 13.98 EPS for the current year.

Institutional Trading of Teleflex

Institutional investors and hedge funds have recently modified their holdings of the stock. Thurston Springer Miller Herd & Titak Inc. increased its stake in shares of Teleflex by 242.9% in the 2nd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 216 shares of the medical technology company’s stock valued at $26,000 after acquiring an additional 153 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its position in shares of Teleflex by 57.9% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock valued at $26,000 after purchasing an additional 77 shares during the period. Banque Cantonale Vaudoise acquired a new stake in Teleflex during the 1st quarter worth approximately $27,000. Costello Asset Management INC acquired a new stake in Teleflex during the 1st quarter worth approximately $28,000. Finally, Brooklyn Investment Group raised its holdings in Teleflex by 258.6% during the 1st quarter. Brooklyn Investment Group now owns 208 shares of the medical technology company’s stock worth $29,000 after buying an additional 150 shares during the period. 95.62% of the stock is owned by institutional investors.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.